| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 46,003 | 43,404 | ||
| Marketable securities, available for sale | 517,337 | 550,588 | ||
| Prepaid expenses and other assets | 10,560 | 9,263 | ||
| Total current assets | 573,900 | 603,255 | ||
| Property and equipment, net | 8,129 | 8,595 | ||
| Operating lease right-of-use asset | 1,437 | 1,484 | ||
| Total assets | 583,466 | 613,334 | ||
| Accounts payable | 6,157 | 8,320 | ||
| Accrued compensation | 7,998 | 5,636 | ||
| Accrued other expenses | 6,483 | 5,936 | ||
| Operating lease liability, current portion | 1,008 | 1,004 | ||
| Total current liabilities | 21,646 | 20,896 | ||
| Operating lease liability, net of current portion | 3,173 | 3,367 | ||
| Preferred stock, .0001 par value per share 200,000,000 shares authorized and no shares issued or outstanding as of june 30, 2025 and december 31, 2024 | - | 0 | ||
| Total liabilities | 24,819 | 24,263 | ||
| Common stock, .0001 par value per share 1,000,000,000 shares authorized as of september 30, 2025 and december 31, 2024 105,761,949 shares and 94,838,466 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 10 | 10 | ||
| Additional paid-in capital | 1,054,091 | 1,044,346 | ||
| Accumulated other comprehensive income | 701 | 204 | ||
| Accumulated deficit | -496,155 | -455,489 | ||
| Total stockholders' equity | 558,647 | 589,071 | ||
| Total liabilities and stockholders' equity | 583,466 | 613,334 | ||
Edgewise Therapeutics, Inc. (EWTX)
Edgewise Therapeutics, Inc. (EWTX)